AstraZeneca, Pharmacor Clash Over Diabetes Drug Patent
Generic drugmaker Pharmacor argued Monday that AstraZeneca's patent for a treatment for type 2 diabetes, heart failure and chronic kidney disease was wrongly extended under the Patents Act, preventing it from...To view the full article, register now.
Already a subscriber? Click here to view full article